{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T00:43:29Z","timestamp":1770079409866,"version":"3.49.0"},"reference-count":33,"publisher":"The Journal of Rheumatology","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Rheumatol"],"published-print":{"date-parts":[[2016,4]]},"abstract":"<jats:sec><jats:title>Objective.<\/jats:title><jats:p>Myeloid-related proteins (MRP) 8\/14 belong to a family of calcium-binding proteins produced by myeloid cells. Baseline serum levels of MRP8\/14 have been shown to predict response to biologicals in rheumatoid arthritis (RA). Because methotrexate (MTX) is the first-line therapy in RA, we studied whether MRP8\/14 levels can predict response to MTX.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods.<\/jats:title><jats:p>Patients with active RA disease who were naive to disease-modifying antirheumatic drugs were enrolled. All patients were treated with MTX only, to a maximum of 25 mg\/week or the maximal tolerated dose. At 4 months, the European League Against Rheumatism response was assessed. All patients who needed rescue therapy after 2 months or who did not respond at 4 months were classified as nonresponders.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results.<\/jats:title><jats:p>Ninety patients were enrolled, of whom 3 discontinued MTX within 4\u20136 weeks, so 87 patients were analyzed [74 women, median (interquartile range; IQR) for the Disease Activity Score at 28 joints (DAS28) was 4.43 (4.1\u20135.1)]. The median (IQR) serum MRP8\/14 level at baseline was 19.95 <jats:italic>\u00b5<\/jats:italic>g\/ml (11.49\u201339.06). The serum MRP8\/14 had good correlation with DAS28-C-reactive protein (CRP; r = 0.35, p = 0.001). The MRP8\/14 levels fell significantly after 4 months of treatment (10.28 <jats:italic>\u00b5<\/jats:italic>g\/ml, 5.95\u201316.05, p &lt; 0.001). Among 87 patients, 69 were responders. The median (IQR) baseline level of MRP8\/14 was higher among responders compared with nonresponders: 23.99 <jats:italic>\u00b5<\/jats:italic>g\/ml (15.39\u201342.75) versus 9.58 <jats:italic>\u00b5<\/jats:italic>g\/ml (6.11\u201324.93, p = 0.00250). The levels declined in the responders, from 23.99 <jats:italic>\u00b5<\/jats:italic>g\/ml (15.39\u201342.75) to 10.41 <jats:italic>\u00b5<\/jats:italic>g\/ml (5.83\u201315.61, p &lt; 0.001), but not in the nonresponders, from 9.58 <jats:italic>\u00b5<\/jats:italic>g\/ml (6.11\u201324.93) to 9.19 <jats:italic>\u00b5<\/jats:italic>g\/ml (7.74\u201321.96, p = 0.687). Receiver-operation characteristic analysis showed that MRP8\/14 was a better predictor of response than CRP and erythrocyte sedimentation rate, especially with early disease onset (&lt; 1-yr duration).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion.<\/jats:title><jats:p>MRP8\/14 is a good marker of disease activity in RA, and higher levels predict response to MTX.<\/jats:p><\/jats:sec>","DOI":"10.3899\/jrheum.150998","type":"journal-article","created":{"date-parts":[[2016,2,1]],"date-time":"2016-02-01T22:15:27Z","timestamp":1454364927000},"page":"731-737","source":"Crossref","is-referenced-by-count":29,"title":["Myeloid-related Protein 8\/14 Levels in Rheumatoid Arthritis: Marker of Disease Activity and Response to Methotrexate"],"prefix":"10.3899","volume":"43","author":[{"given":"Pradeepta Sekhar","family":"Patro","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ankita","family":"Singh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ramnath","family":"Misra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amita","family":"Aggarwal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2262","published-online":{"date-parts":[[2016,2,1]]},"reference":[{"key":"2018112909353158000_43.4.731.1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1004965"},{"key":"2018112909353158000_43.4.731.2","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keh199"},{"key":"2018112909353158000_43.4.731.3","doi-asserted-by":"publisher","DOI":"10.3960\/jslrt.51.77"},{"key":"2018112909353158000_43.4.731.4","doi-asserted-by":"publisher","DOI":"10.1189\/jlb.1209775"},{"key":"2018112909353158000_43.4.731.5","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780351003"},{"key":"2018112909353158000_43.4.731.6","first-page":"691","article-title":"The effects of low-dose methotrexate on thymidylate synthetase activity in human peripheral blood mononuclear cells","volume":"18","author":"Hornung","year":"2000","journal-title":"Clin Exp Rheumatol"},{"key":"2018112909353158000_43.4.731.7","doi-asserted-by":"publisher","DOI":"10.1124\/pr.57.2.3"},{"key":"2018112909353158000_43.4.731.8","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780371013"},{"key":"2018112909353158000_43.4.731.9","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2010.139212"},{"key":"2018112909353158000_43.4.731.10","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kep112"},{"key":"2018112909353158000_43.4.731.11","doi-asserted-by":"crossref","first-page":"978396","DOI":"10.1155\/2012\/978396","article-title":"Markers of treatment response to methotrexate in rheumatoid arthritis: where do we stand?","volume":"2012","author":"Halilova","year":"2012","journal-title":"Int J Rheumatol"},{"key":"2018112909353158000_43.4.731.12","doi-asserted-by":"publisher","DOI":"10.1002\/art.22640"},{"key":"2018112909353158000_43.4.731.13","doi-asserted-by":"publisher","DOI":"10.1002\/art.20631"},{"key":"2018112909353158000_43.4.731.14","doi-asserted-by":"publisher","DOI":"10.1038\/emm.2013.39"},{"key":"2018112909353158000_43.4.731.15","doi-asserted-by":"publisher","DOI":"10.1038\/nm.2150"},{"key":"2018112909353158000_43.4.731.16","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2007.077800"},{"key":"2018112909353158000_43.4.731.17","doi-asserted-by":"publisher","DOI":"10.1038\/330080a0"},{"key":"2018112909353158000_43.4.731.18","first-page":"2523","article-title":"Expression of myeloid related proteins (MRP) 8 and 14 and the MRP8\/14 heterodimer in rheumatoid arthritis synovial membrane","volume":"26","author":"Youssef","year":"1999","journal-title":"J Rheumatol"},{"key":"2018112909353158000_43.4.731.19","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2006.064741"},{"key":"2018112909353158000_43.4.731.20","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2008.103739"},{"key":"2018112909353158000_43.4.731.21","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-203923"},{"key":"2018112909353158000_43.4.731.22","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2010.138461"},{"key":"2018112909353158000_43.4.731.23","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780380107"},{"key":"2018112909353158000_43.4.731.24","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(199810)41:10<1845::AID-ART17>3.0.CO;2-K"},{"key":"2018112909353158000_43.4.731.25","doi-asserted-by":"publisher","DOI":"10.1186\/ar3426"},{"key":"2018112909353158000_43.4.731.26","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keg385"},{"key":"2018112909353158000_43.4.731.27","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.159.21.2542"},{"key":"2018112909353158000_43.4.731.28","doi-asserted-by":"publisher","DOI":"10.1136\/ard.62.5.423"},{"key":"2018112909353158000_43.4.731.29","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2008.088237"},{"key":"2018112909353158000_43.4.731.30","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2010.375"},{"key":"2018112909353158000_43.4.731.31","doi-asserted-by":"publisher","DOI":"10.1186\/ar2645"},{"key":"2018112909353158000_43.4.731.32","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/ket375"},{"key":"2018112909353158000_43.4.731.33","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-204573"}],"container-title":["The Journal of Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.3899\/jrheum.150998","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,11,29]],"date-time":"2018-11-29T14:05:48Z","timestamp":1543500348000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.jrheum.org\/lookup\/doi\/10.3899\/jrheum.150998"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,2,1]]},"references-count":33,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2016,4,1]]},"published-print":{"date-parts":[[2016,4]]}},"alternative-id":["10.3899\/jrheum.150998"],"URL":"https:\/\/doi.org\/10.3899\/jrheum.150998","relation":{},"ISSN":["0315-162X","1499-2752"],"issn-type":[{"value":"0315-162X","type":"print"},{"value":"1499-2752","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,2,1]]}}}